Squarepoint Ops LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 3.70 and the average weighting 0.2%.

Quarter-by-quarter ownership
Squarepoint Ops LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$5,282,402
+3704.2%
746,102
+3682.7%
0.01%
Q2 2023$138,857
-89.0%
19,724
-86.9%
0.00%
-100.0%
Q1 2023$1,257,464
-60.6%
150,775
-45.7%
0.01%
-61.5%
Q4 2022$3,188,467
+45.3%
277,741
+59.5%
0.01%
+18.2%
Q3 2022$2,195,000
-55.4%
174,167
-42.5%
0.01%
-47.6%
Q1 2022$4,927,000
+635.4%
303,008
+526.5%
0.02%
+950.0%
Q4 2021$670,000
+16.1%
48,366
-14.8%
0.00%
-33.3%
Q1 2021$577,000
+249.7%
56,770
+156.2%
0.00%
+200.0%
Q4 2020$165,000
+323.1%
22,155
+94.3%
0.00%0.0%
Q3 2020$39,000
-90.4%
11,400
-86.6%
0.00%
-85.7%
Q2 2020$405,000
+131.4%
84,972
-3.0%
0.01%
+75.0%
Q1 2020$175,000
-91.8%
87,573
-85.9%
0.00%
-69.2%
Q4 2019$2,135,000
+109.1%
618,943
+73.7%
0.01%
+44.4%
Q3 2019$1,021,000
+526.4%
356,421
+726.7%
0.01%
+350.0%
Q2 2019$163,000
-82.2%
43,113
-61.6%
0.00%
-80.0%
Q1 2019$914,000
+139.9%
112,245
+137.9%
0.01%
+150.0%
Q4 2018$381,000
-17.5%
47,190
-22.1%
0.00%
-33.3%
Q3 2018$462,000
-35.8%
60,611
-51.8%
0.01%
-40.0%
Q2 2018$720,000
+109.9%
125,714
+92.3%
0.01%
+42.9%
Q3 2017$343,000
+75.9%
65,389
+86.8%
0.01%
+75.0%
Q2 2017$195,000
+38.3%
34,999
+108.3%
0.00%0.0%
Q1 2017$141,000
-37.1%
16,800
-52.6%
0.00%
-55.6%
Q4 2016$224,000
+91.5%
35,425
-14.0%
0.01%0.0%
Q1 2016$117,000
-58.4%
41,197
+51.5%
0.01%
-71.0%
Q4 2015$281,00027,2000.03%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2017
NameSharesValueWeighting ↓
RP Management, LLC 3,846,154$62,538,00025.44%
ORACLE INVESTMENT MANAGEMENT INC 1,720,733$27,979,0005.53%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 57,000$19,282,0004.35%
MPM BioImpact LLC 639,089$10,392,0002.79%
Parkman Healthcare Partners LLC 476,978$7,756,0002.27%
Sarissa Capital Management LP 1,390,790$22,614,0002.14%
Ghost Tree Capital, LLC 350,000$5,691,0001.24%
Lisanti Capital Growth, LLC 662,644$10,775,0001.21%
Baker Brothers Advisors 12,710,818$206,678,0001.19%
Tamarack Advisers, LP 125,000$2,033,0000.96%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders